secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001193125-24-082784
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks removes CFO Christopher Astle; CEO Kenneth Galbraith named interim CFO
--------------------------------------------------------------------------------

- Dr. Christopher Astle removed as SVP and CFO, including principal financial and accounting officer, effective March 31, 2024.
- Kenneth Galbraith, Chair, President, and CEO, appointed interim CFO, assuming principal financial and accounting duties.
- Company has initiated a search for a new permanent CFO.
- Mr. Galbraith's compensation arrangements remain unchanged per prior filings.
- No family relationships or arrangements with other persons regarding the appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312524082784/0001193125-24-082784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312524082784/d806103d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-082784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer